Disappointing results from phase 3 CheckMate 73L study of concurrent nivolumab + chemoradiation for stage III NSCLC & nivol +/- ipilimumab vs durvalumab consolidation. No improvement in PFS over standard PACIFIC approach. Similar to negative PACIFIC-2.

news.bms.com/news/corporate…

Decoding #Biomarkers and #TargetedTherapy in #NSCLC with Stephen V Liu, MD, Benjamin Levy, JessicaJLinMD & Solange Peters live in person & online during #ASCO24 on June 1 at 6:30 PM CDT. Produced with LUNGevity Foundation bit.ly/2024BiomarkersT

Report of #KRAS G12C inhibitor D3S-001 now Cancer Discovery. Encouraging preclinical target engagement kinetics, in vivo CNS efficacy, and report of 2 durable responses in patients enrolled in the phase I study (one > 16m). Looking forward to more data.

aacrjournals.org/cancerdiscover…

Does targeting #MET signaling enhance anti-tumor immune responses? Single arm trial of capmatinib + nivolumab in pts with NSCLC post-chemotherapy Lung Cancer Journal showed in high-MET, RR 25% with 6m PFS 69% and in low-MET, RR 16.7% with 6m PFS 51%.

lungcancerjournal.info/article/S0169-…

Grateful once again for IASLC endorsement of the DC Lung Cancer Conference! #DCLung24 features our largest faculty roster yet for a comprehensive, one-day, #CME #MOC update on thoracic malignancies. Saturday, October 19th, in downtown Washington, DC.

medstarhealth.org/dclung24

Ph III IMscin001 trial of Subcutaneous (sc) vs IV Atezolizumab in adv NSCLC JTO & JTO CRR:

- mOS 10.7 v 10.1m
- median admin time sc: 7mins
- similar toxicity

A step forward in implementing anti-PD(L)1 across growing nos. of indications?

OncoAlert #LCSM
jto.org/article/S1556-…

Renew your IASLC membership now & unlock a range of benefits including discounted registration for events, access to journals, and more. Join us & make a difference in #lungcancer treatment & research!

RENEW or JOIN Today: iaslc.org/membership

US FDA accepts for priority review BLA of zenocutuzumab (HER2/3 bispecific antibody) for patients with #NRG1 fusion NSCLC or pancreatic cancer. Fusions in NRG1 (neuregulin) are rare but important, can be missed by DNA NGS, best detected with RNA-seq.

ir.merus.nl/news-releases/…

Update from phase 3 IMscin001 trial JTO & JTO CRR. Pts with NSCLC randomized 2:1 to subcutaneous vs IV atezolizumab. Similar OS (10.7 vs 10.1m) and safety. Subcutaneous typically took 4-8 minutes; felt more convenient, with higher satisfaction scores.

jto.org/article/S1556-…

Interesting multi-omic analysis of previously classified SCLC cell lines (YAP1+), identifies that these tumors represent diseases that ‘mimic’ SCLC- in this case- SMARCA4-deficient thoracic tumors, that have a poor prognosis

Clinical Cancer Research OncoAlert #LCSM

aacrjournals.org/clincancerres/…

Grateful once again for IASLC endorsement of the DC Lung Cancer Conference! #DCLung24 features our largest faculty roster yet for a comprehensive, one-day, #CME #MOC update on thoracic malignancies. Saturday, October 19th, in downtown Washington, DC.

medstarhealth.org/dclung24

Register for the IASLC 2024 CT Screening Symposium at #WCLC24 on September 7 in San Diego, CA. For updates to the current standards and a discussion of future directions in lung cancer screening - register here:
bit.ly/CTSS24 [bit.ly] #CTSS24 #LCSM

Your Perspective Matters! Your Impact Counts! Join us in shaping a more inclusive & welcoming #IASLC community! Share your feedback on the global survey on inclusivity, where every voice counts. Take the survey & be the change you wish to see! bit.ly/DEISurvey24

On 10 May at Istituto Tumori and online for the second edition of the 'AI for Oncology' conference, we will explore how AI is transforming cancer. Under the auspices of ASCO, IASLC and AIOM. registrations to the event are still accepted @ aiforoncology.it ! #AI4Oncology

Join us tomorrow, May 8, 2024 (1-2 PM EDT/7-8 PM CET), for an educational webinar on the treatment of thymic tumors, featuring Drs. Mara Antonoff (Mara Antonoff, MD, FACS), Stephen Chun, and Chul Kim (@chulkimMD).

➡️Registration: bit.ly/44fL32J

ITMIG Society

With all of the lung cancer updates this year, be sure to join us in downtown Washington, DC on Saturday, October 19th, 2024 for #DCLung24 for a one-day #CME with all the latest data presented by world class experts! Agenda and registration below:

medstarhealth.org/dclung24

Nice session of presentations and discussions this morning at #RomeLung24 on lung cancer IO and ADCs…impressive number of KOLs to discuss and exchange...so many questions about strategies for our patients !

Great overview of resistance mechanisms to #KRAS inhibitors in #NSCLC at #RomeLung24 by AmbrogioLab. Different therapeutic vulnerabilities depending on whether resistance is intrinsic, acquired, or adaptive.